Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng,Zhanyu Pan,Lin Wu,Bo Zhu,Yan Yu, Kai Zang,Wu Zhuang,Lianke Liu,Kangsheng Gu,Juanwen Lian,Rixin Chen, Tao Bian,Dang Lin,Shenghua Sun,Wei Li,Xiaosheng Hang,Ou Jiang,Fukuan Zhong,Rui Wang,Hui Luo,Huaqiu Shi,Zonghui Wei,Li Zhao,Shaoshui Chen,Hongmei Sun,Xingya Li,Debin Sun,Tiejun Ren,Kaijian Lei, Miao He,Gaofeng Li, Hailong Liu, Runpu Li,Chunhong Hu,Li Kong,Meili Sun,Liangzhi Xie,Wenlin Gai, Weiqiu Chen, Zhe Huang, Wenwen Ren, Huo SuAdvances in Therapy（2024）引用 0|浏览6暂无评分关键词Non-small cell lung cancer,SCT510,Immunotherapy,Randomized controlled trialAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
